Agenus posts investor deck spotlighting botensilimab-balstilimab neoadjuvant program in MSS colon cancer

• Agenus outlined a registrational Phase 3 “ROBBIN” trial of botensilimab with balstilimab in neoadjuvant MSS colon cancer.
• Trial design: n=850, randomized 1:1, primary endpoint event-free survival; first patient in projected by Q1 2027.
• Across NEST and UNICORN investigator studies, 38 MSS colon patients showed about 30% pCR, about 40% MPR, 100% EFS at 9-18 months.
• Tolerability in neoadjuvant studies: low Grade ≥3 adverse events; one surgery delay of 10 days among 52 treated patients.
• July PIPE financing expected to fund ROBBIN trial costs, operations through end-2031, assuming full warrant exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.